ClinicalTrials.gg
CompletedNCT04146285Updated Jul 10, 2025

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

A Phase 1 interventional study of BAT4406F in Neuromyelitis Optica Spectrum Disorders, sponsored by Bio-Thera Solutions. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Neuromyelitis Optica with a site in China — 37 open to participants now, 43 under way, 7 of them phase 3. Neuromyelitis Optica · China.

Enrollment
33rd of 51
15 · median 23
Started
2020
with 6 others
Phase 1
17 of 72
10 open now
Registered
13th of 72
by date

Among the 72 studies in Neuromyelitis Optica with a site in China, this one is the 33rd largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2020, is one of 17 in phase 1, and was the 13th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

37 of the 72 studies in Neuromyelitis Optica with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neuromyelitis Optica with a site in China, or all of them as a file.
02

Study summary

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.

Read the detailed description

This is a Phase 1, open-label, dose-escalation study in NMOSD patients in which subjects will receive BAT4406F injection via intravenous infusion. A 3 + 3 design will be utilized to define a maximum tolerated dose (MTD). The overall objective is to assess the safety, tolerability, and pharmacokinetics of BAT4406F injection in NMOSD patients.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Compliance with the NMOSD diagnostic criteria developed by the 2015 International NMO Diagnostic Team (IPND);
  • 18-65 years old , male or female;
  • At least 2 relapses occurred within 2 years before screening, or at least 1 relapse within 1 year before screening;
  • Discontinue the agents such as azathioprine within 28 days before the baseline;
  • EDSS score ≤ 6;
  • Men and women with fertility must agree to use effective methods of during treatment and within 12 months of treatment completion;
  • Agree to participate in the trial and sign the in writing.

Exclusion criteria

Exclusion Criteria:

  • Any monoclonal antibody treatment was used within 6 months prior to dosing;
  • Having been treated with anti-CD20 monoclonal antibody;
  • received within 4 weeks before screening;
  • Having participated in another clinical study within 1 month or 5 half-lives of the drug prior to the baseline (whichever is longer);
  • A history of allergies to monoclonal antibodies; severe allergic reaction to certain foods or drugs;
  • Abnormal liver function, kidney function and bone marrow reserve;
  • -positive history or HIV-positive at screening; and/or history or hepatitis B surface antigen-positive at screening; or hepatitis C virus (HCV) antibody positive; treponema pallidum antibody positive when enrolled;
  • History of infections that investigators have identified as unsuitable for testing;
  • Patients with a clear history of heart disease ;
  • Have a history of mental disorders;
  • Pregnant or lactating women, and female subjects who have a positive pregnancy test at screening;
  • None of the investigators or their relatives participating in the study could be enrolled.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    BAT4406F

    Drug: BAT4406F

Interventions

  • Open-label dose escalation starting from 20mg. Route of administration: intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    Safety and tolerability endpoint

    Time frame: 4weeks

  2. Maximum tolerated dosed (MTD)

    Safety and tolerability endpoint

    Time frame: up to 6 months

  3. Area under the curve (AUC)

    Pharmacokinetic endpoint

    Time frame: up to 6 months

  4. Maximum serum drug concentration (Cmax)

    Pharmacokinetic endpoint

    Time frame: up to 6 months

  5. Half-life period(t1/2)

    Pharmacokinetic endpoint

    Time frame: up to 6 months

  6. Maximum serum drug time (Tmax)

    Pharmacokinetic endpoint

    Time frame: up to 6 months

  7. CD19+ B lymphocyte ratio

    Pharmacodynamics endpoint

    Time frame: up to 6 months

07

Study locations

1 site
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
08

References and documents

Publications

  • Yu H, Chen Y, Qi Y, Yang H, Cao G, Yang W, Li S, Yang X, Wang H, Zhang J, Chen X. First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders. CNS Neurosci Ther. 2024 Nov;30(11):e70126. doi: 10.1111/cns.70126. PubMed 39592888 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Oct 31, 2019
StartActual
Sep 1, 2020
Primary completionActual
Mar 13, 2023
CompletionActual
Dec 25, 2023
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04146285
Responsible party
Sponsor
First posted
Oct 31, 2019
Start date
Sep 1, 2020
Primary completion
Mar 13, 2023
Completion
Dec 25, 2023
Last update
Jul 10, 2025

Study contacts

Xiangjun Chen
principal investigator · Huashan Hospital
Jing Zhang
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAT4406F

Start the discussion